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Apoptotic resistance is becoming a significant
obstacle for cancer therapy as the majority of treat-
ment takes the route of apoptotic induction. It is of
great importance to develop an alternative strategy
to induce cancer cell death. We previously reported
that autophagic cell death mediated by nuclear
receptor TR3 and driven by a chemical agonist,
1-(3,4,5-trihydroxyphenyl)nonan-1-one (THPN), is
highly effective in the therapy of melanoma but not
any other cancer types. Here, we discovered that
the insensitivity of cancer cells to THPN originated
from a high cellular Akt2 activity. Akt2 phosphoryla-
tion interferes with TR3 export to cytoplasm and tar-
geting to mitochondria, which lead to the autophagic
induction. Therefore, the TR3-mediated autophagy
could be effectively induced in the otherwise insensi-
tive cells by downregulating Akt2 activity. Highly
effective antineoplastic compounds are developed
through optimizing the structure of THPN. This study
implicates a general strategy for cancer therapy by
the induction of autophagic cell death.
INTRODUCTION
The serine/threonine kinase Akt (also called protein kinase B,
PKB) is a critical signaling node in higher eukaryotes and is
one of the most activated effectors in the oncogenic landscape.
There are three Akt isoforms (Akt1/2/3), which share 80%
sequence homology but are functionally distinct (Gonzalez and
McGraw, 2009; Manning and Cantley, 2007). Homozygous
knockout of individual Akt genes in mice reveals that Akt1 plays
an important role in cell survival, Akt2 is primarily involved in in-
sulin tolerance, and Akt3 participates in brain development
(Chen et al., 2001; Cho et al., 2001; Tschopp et al., 2005). Can-
cers harboring a mammary-specific Akt1 transgene was with
an accelerated tumorigenesis but, somewhat paradoxically,
decreased metastatic dissemination (Hutchinson et al., 2004).
The decreased function of Akt1 in migration and invasion of1040 Chemistry & Biology 22, 1040–1051, August 20, 2015 ª2015 Elbreast cancer is through the Akt1-mediated MDM2 phosphory-
lation and degradation of NFAT, a transcription factor for
enhancing cell migration (Yoeli-Lerner et al., 2005). Instead of
increasing the incidence of pulmonary metastases, mammary-
specific expression of the Akt2 gene did not alter the latency of
mammary tumor formation (Dillon et al., 2009). This Akt2-facili-
tated invasion of breast cancer cells is likely through phosphor-
ylation and upregulation of b1 integrins (Arboleda et al., 2003).
Therefore, the distinct roles of Akts in modulating cancer pro-
gression are likely to be target specific. Different Akts may use
different phosphorylation mechanisms to regulate different func-
tions in different substrates.
Genetic aberration of Akt2, which is associated with aggres-
siveness and poor prognosis, has been detected in many tumor
types, including ovarian, breast, colorectal, hepatocyte, lung,
and pancreatic cancers (Altomare et al., 2002; Arboleda et al.,
2003; Lee et al., 2011; Parsons et al., 2005; Xu et al., 2004).
Akt2 also has abnormally high expression and enhanced kinase
activity in a variety of malignancies compared with other two iso-
forms. For example, the Akt2 activity is 10% higher in pancreatic
tumors, 40% higher in hepatocellular carcinomas, and 57%
higher in colorectal adenocarcinomas (Cheng et al., 1996; Roy
et al., 2002; Xu et al., 2004). While playing critical roles in tumor
growth, metastasis, and anti-apoptosis, Akt2 is also the source
of chemoresistance (Marfe et al., 2011; Yuan et al., 2003). A bet-
ter understanding on the Akt2-mediated resistance will facilitate
the development of novel cancer therapy.
TR3 (also namedNur77 or NGFI-B) is an orphan nuclear recep-
tor in the steroid/thyroid/retinoid nuclear receptor superfamily.
TR3 participates in a variety of biological processes, including
cell proliferation, differentiation, and apoptosis (Hanna et al.,
2011; Kolluri et al., 2003; Li et al., 2000). The function of TR3 is
often modulated by post-transcriptional modification, especially
phosphorylation. Phosphorylation of Ser351 by Akt1 impairs TR3
binding to DNA and phosphorylation at the N terminus blocks the
cytoplasmic TR3 targeting to mitochondria to suppress the role
of TR3 in apoptosis (Chen et al., 2008; Pekarsky et al., 2001).
However, the molecular mechanism for Akt2 modulation of
TR3 function is poorly understood thus far.
A number of TR3-targeting compounds have been identified,
which facilitates the development of therapeutics. The first
agonist to TR3 is cytosporone B, which induces apoptosis by
either transactivating the TR3-targeting genes or inducing TR3sevier Ltd All rights reserved
translocation to mitochondria (Liu et al., 2010; Zhan et al., 2008).
The compound 1,1-bis(30-indolyl)-1-(p-anisyl)methane pro-
motes the induction of programmed cell death gene 1 in a
TR3-dependent manner for inhibiting the proliferation and xeno-
graft growth of pancreatic cells (Cho et al., 2007). Besides
anti-tumorigenicity, the TR3-targeting compound, ethyl 2-[2,3,4
trimethoxy-6(1-octanoyl) phenyl]acetate, participates in control-
ling gluconeogenesis and diabetes through disrupting the TR3-
LKB1 interaction, by which LKB1 is released and shuttled to
the cytoplasm to phosphorylate and activate AMPKa (Zhan
et al., 2012). The compound 6-mercaptopurine plays a potential
role in in-stent restenosis therapy by reducing the excessive pro-
liferation of smooth muscle cells in a TR3-dependent fashion
(Yoo et al., 2007). These data indicate that TR3 is a multi-func-
tional drug target. A viable therapeutic strategy is to manipulate
the expression level, transactivation activity, subcellular localiza-
tion, or interaction of TR3 with other proteins.
We recently reported a TR3-specific targeting compound,
1-(3,4,5-trihydroxyphenyl)nonan-1-one (THPN), that can induce
autophagic cell death through amitochondrial signaling pathway
(Wang et al., 2014). However, THPN is only effective for mela-
noma. It is of great significance that THPN induces autophagic
cell death in other apoptotic-resistant cancers, if its application
can be expanded beyond melanoma with an understanding of
the underlying molecular basis. Here, we discovered that Akt2
plays an interfering role in THPN-induced autophagic death
through phosphorylating TR3. By suppressing the Akt2 activity
in non-melanoma cancer cell lines, the THPN-associated auto-
phagic cell death can be induced in the manner similar to that
in melanoma cells. A series of THPN derivatives are developed
for the therapeutic design. This study provides an insight into
the mechanism of Akt2-related resistance to autophagy through
interfering with the TR3-mediated signal transduction pathway,
and demonstrates a new avenue to broaden THPN application
to treat many cancer types other than melanoma by co-adminis-
tering an Akt inhibitor.
RESULTS
A Key Factor for Cellular Resistance to THPN-Induced
Cell Death
We demonstrated that THPN effectively inhibited the viability of
melanoma cells but not any other types of cancer cells through
a TR3-mediated autophagic pathway (Wang et al., 2014). In
that report, translocation from cytoplasm to mitochondria was
shown to be a determinant for TR3 response to THPN. However,
amere cytoplasmic accumulation of TR3, as induced by tetrade-
canoylphorbol acetate, did not necessary result in the THPN-
induced autophagic cell death in other types of cancer cell lines
such as HeLa cells (Figure S1A; similar results in other cancer
cells are not shown). Even the transfection of a TR3 mutant
(TR3-DNLS) that exclusively remained in the cytoplasm with
the deletion of the nuclear localization signal (NLS) did not lead
to the THPN-induced cell death in TR3 knocked downHeLa cells
compared with A375 melanoma cells (Figure S1B). Thus, cyto-
plasmic localization alone is not sufficient for TR3 response to
THPN stimulation, and there are other factors that furnish
the resistance to THPN-induced cell death in non-melanoma
cancer cells.Chemistry & Biology 22, 1040–Phosphorylation is a key medium in cellular signal transduc-
tion. The phosphorylation activities for various kinases in
different cancer cell lineswere analyzed. Akt phosphorylation ac-
tivities at T308 and S473 were at much lower levels in melanoma
cell lines than in non-melanoma cell lines. Such a phenomenon
was not observed for ERK, p38, and JNK (Figure 1A). However,
the protein expression levels of these kinases were unchanged
in all of the cell lines tested. Pretreatment of Akt inhibitor,
LY294002, but not inhibitors to any other kinases, showed signif-
icant THPN-induced suppression of viability in non-melanoma
cells, such as gastric cancer SGC7901 cells and cervical cancer
HeLa cells, in the manner similar to the THPN-induced autopha-
gic cell death in melanoma (Figure 1B; similar results in other
cancer cells are not shown) (Wang et al., 2014). Pretreatment
of SGC7901 and HeLa cells with LY294002 followed by THPN
significantly enhanced the formation of cytoplasmic puncta
with the conversion of LC3-I to LC3-II (Figure 1C), which could
not be observed with the treatment with staurosporine and VP-
16, two apoptotic stimulators that induced chromatin condensa-
tion (Figure S1C), casepase-3 and PARP cleavage (Figure S1D),
and apoptosis-inducing factor release from the mitochondria
(Figure S1E). Moreover, LY294002 and THPN-induced cell death
was attenuated by knocking down ATG5 or ATG7, two of the
essential autophagic proteins, but not by knocking down RIP1,
RIP3, BAX, and caspase-3, the essential necrotic or apoptotic
proteins (Figures S1F and S1G). We conclude that higher Akt ac-
tivity in non-melanoma cancer cells impairs cancer cell response
to THPN-induced autophagic cell death.
Akt2 Phosphorylation Impedes TR3 Cytoplasmic
Translocation and Mitochondrial Targeting
We demonstrated that LY294002 inhibition of Akt activity in the
presence of THPN facilitated the TR3 cytoplasmic translocation
(Figure S2A), association with Nix (Figure S2B), and targeting to
mitochondria (Figure 2A) in SGC7901 and HeLa cells. The result-
ing dissipation of the mitochondrial membrane potential (DJm),
a cause of autophagy, induced by both LY294002 and THPN,
was shown with either JC-1 (Figure 2B, left) or DiOC6 staining
(Figure S2C, top), which resulted in a partial redistribution of
the LysoTracker fluorescence from a vesicular to a mixed cyto-
solic/vesicular pattern (Figure 2B, right) and a shift from dye
diffusion to the loss of dotted architecture of lysosomal acridine
orange (AO) signal (Figure S2C, bottom) in these two cell lines
(Noonan et al., 2010).
There are also indications that LY294002 inhibition of Akt ac-
tivity did more than just facilitate the TR3 cytoplasmic transloca-
tion, as neither LY294002 nor THPN alone were able to induce
the TR3 mitochondrial location when the endogenous TR3 was
first knocked down and the mutant TR3-DNLS was transfected
into HeLa cells. Only the combined application of LY294002
and THPN could initiate TR3 targeting tomitochondria, LC3 con-
version, DJm dissipation, redistribution of LysoTracker fluores-
cence, and cell death (Figure S2D). Therefore, Akt interferes with
both the TR3 cytoplasmic translocation and THPN-induced TR3
targeting to mitochondria to prevent cancer cells from undergo-
ing autophagic death.
The isoform in the Akt family that participates in the THPN-
induced autophagy was further determined. Each Akt isoform
was separately knocked down by shRNA with the lentivirus1051, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1041
Figure 1. THPN Requires LY294002 to
Induce Autophagic Cell Death in Various
Cancer Cell Lines
(A) The activities of various kinases between mel-
anoma and non-melanoma cells. The activities of
Akt, ERK, p38, and JNK were determined by spe-
cific antibodies to phospho-Akt (T308 or S473),
phospho-ERK, phospho-p38, and phospho-JNK.
The expression levels of the proteins indicated
were determined by western blot. IB, immunoblot.
(B) Akt inhibitor significantly influenced the THPN-
induced suppression of viability in non-melanoma
cancer cells. Inhibitor to Akt (LY294002, 20 mM),
but not those to p38 (SB202190, 20 mM), ERK
(PD98059, 40 mM), and JNK (25 mM), were used in
conjunction with THPN to induce cell death in
SGC7901 (top) andHeLa (bottom) cancer cell lines.
Cells were separately pretreated with each inhibi-
tor for 1 hr before the THPN treatment (20 mM,
48 hr). Cell viability is analyzed by flow cytometry.
(C) LY294002 induces cell autophagy in conjunc-
tion with THPN. SGC7901 (top) or HeLa cells
(bottom) were pretreated with LY294002 (20 mM,
1 hr) followed by THPN treatment (20 mM, 24 hr).
Left: The change of GFP-LC3 fusion proteins from
a diffuse pattern to cytoplasmic puncta observed
under confocal microscope (scale bars,10 mm).
Middle: Calculation of GFP-LC3-positive cells with
puncta from five randomly picked regions. Right:
determination of LC3 conversion by western blot.
All data are presented as the mean ± SEM of three
independent experiments. **p < 0.01, ***p < 0.001;
NS, not significant. See also Figure S1.system in HeLa cells (Figure S2E). Only the knockdown of Akt2,
but neither Akt1 nor Akt3, effectively enhanced THPN-associ-
ated cell death (Figure 2C, top), as the downregulation of Akt2
allowed THPN to induce TR3 mitochondrial targeting (Figure 2C,
bottom) with the coincident DJm dissipation and redistribution
of the LysoTracker fluorescence (Figure 2D), as well as the
GFP-LC3 puncta conversion from LC3-I to LC3-II (Figure 2E).
The cell death resulting from the Akt2 knockdown and THPN
treatment was attenuated by an inhibitor to autophagy (chloro-
quine), but not inhibitors to apoptosis (zVAD) and necrosis (butyl-
ated hydroxyanisole) (Figure S2F). Clearly it is Akt2 that prevents
THPN-induced autophagic cell death in non-melanoma cancers
through the TR3-mediated mitochondrial signaling pathway.
Akt2 Phosphorylates TR3 at a Novel Site to Impair Its
Function
Akt phosphorylates its substrate with a consensus RXRXXS/T
motif (Manning and Cantley, 2007). An antibody specific for the1042 Chemistry & Biology 22, 1040–1051, August 20, 2015 ª2015 Elsevier Ltd All rights resephosphor-RXXS/T motif was employed
to determine the state of Akt2 phosphory-
lation in TR3. Knockdown of Akt2, but not
of Akt1 or Akt3, abolished the endoge-
nous TR3 phosphorylation at the RXXS/T
motif in HeLa cells, while reintroduction
of Akt2 into Akt2-knocked down HeLa
cells efficiently restored the TR3 phos-
phorylation (Figure S3A, left). Consis-tently, Akt Inhibitor XII (a specific inhibitor for Akt2) (Cenni
et al., 2011) also inhibited the TR3 phosphorylation in HeLa
and SGC7901 cells (Figure S3A, right). In addition, in A375 cells
with low Akt activity, both Akt2 and Myr-Akt2 (myristoylated
Akt2) (Park et al., 2008) significantly phosphorylated TR3, which
could only be blocked by LY294002 with the transfection of Akt2
but not Myr-Akt2, as Myr-Akt2 is constitutively active and inde-
pendent of phosphoinositide-3-kinase (PI3K) (Figure S3B). The
in vitro Akt2 phosphorylation of TR3was also demonstrated (Fig-
ure 3A). Therefore, TR3 is a substrate of Akt2.
The molecular basis for Akt2 impairment of TR3 function was
investigated. Akt2 interacted with TR3 in vivo and in vitro, as
shown by co-immunoprecipitation and glutathione S-trans-
ferase (GST) pull-down assays (Figure S3C). We demonstrated
that in melanoma A375 cells, NIP3-like protein X (Nix) functions
as carrier for TR3 targeting to mitochondria with its interaction
with the ligand-binding domain of TR3 (LBD) (Wang et al.,
2014). Like Nix, Akt2 also interacts with LBD (Figure S3D), whichrved
Figure 2. Akt2 Interferes with THPN-Induced Autophagy
(A) LY294002 is required for THPN-induced TR3 translocation to mitochondria. SGC7901 and HeLa cells were treated with THPN (20 mM, 6 hr) after pretreatment
with LY294002 (20 mM, 1 hr). Mitochondrial translocation of TR3 was assayed by western blot. Hsp60 and tubulin were used as the loading controls for mito-
chondrial extracts (Mito) and total cell extracts (Total).
(B) LY294002 induces the dissipation of DJm and lysosomal membrane permeability (LMP) with the presence of THPN. SGC7901 (top) and HeLa (bottom) cells
are pretreated with LY294002 (20 mM, 1 hr), followed by staining with JC-1 (left) or LysoTracker red (right; scale bar, 10 mm) after THPNtreatment (20 mM) for 12 or
24 hr, respectively. The nuclei were simultaneously stained with DAPI (blue).
(C) Knockdown of Akt2 is required for the THPN-induced cell death and TR3 translocation to mitochondria. Endogenous Akt isoforms were separately knocked
down by their corresponding shRNAs before THPN treatment (20 mM) in HeLa cells. The rate of cell survival (top) and TR3 targeting tomitochondria (bottom) were
determined after THPN treatment for 48 and 6 hr.
(D) Knockdown of Akt2 facilitates DJm dissipation and LMP upon THPN treatment. Endogenous Akt2 was knocked down by shRNA in HeLa cells. After THPN
(20 mM) treatment for either 12 or 24 hr, the dissipation of DJm or LMP, respectively, were analyzed (scale bars, 10 mm).
(E) Knockdown of Akt2 is required for the THPN-induced formation of LC3 foci (top and middle) and LC3 conversion (bottom). Endogenous Akts were separately
knocked down by their corresponding shRNAs before THPN treatment (20 mM) in HeLa cells, then GFP-LC3 foci and LC3 conversion were detected as described
above (scale bars, 10 mm).
All data are presented as the mean ± SEM of three independent experiments. **p < 0.01; ***p < 0.001; NS, not significant. See also Figure S2.
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Figure 3. S533 at TR3 Is Critical for Akt2 Phosphorylation
(A) Akt2 phosphorylates TR3 in vitro. His-TR3 was incubated with purified Akt2 at 30C for 30 min for analysis with the antibody to phospho-RXXS/T.
(B) Activation of Akt2 abolishes TR3 interactionwith Nix and targeting to themitochondria. HeLa cells were transfectedwith various plasmids. Left: Cells were first
treated with LY294002 (20 mM, 1 hr) and then THPN (20 mM, 3 hr). TR3-Nix interaction was detected by co-immunoprecipitation. Right: Mitochondrial TR3 was
assayed by western blot after treatment with LY294002 (20 mM, 1 hr) followed by THPN (20 mM, 6 hr).
(C) Akt2 phosphorylates LBD but not LBDS533A. His-LBD and His-LBDS533A were incubated with purified Akt2 at 30C for 30 min and analyzed by western blot
using the antibody to phospho-RXXS/T.
(D) THPN induces interaction between TR3S533A and Nix without LY294002. HeLa cells transfected with various plasmids were treated with LY294002 (20 mM,
1 hr) before THPN stimulation (20 mM, 3 hr). The cell lysates were analyzed by co-immunoprecipitation.
(E) TR3S553A, but not TR3S533D, rescues the THPN-induced TR3 targeting to mitochondria without LY294002. HeLa cells transfected with various plasmids were
treated with LY294002 (20 mM, 1 hr) before THPN stimulation (20 mM, 6 hr). The mitochondrial fragment was prepared and analyzed by western blot.
(legend continued on next page)
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suggests that Akt2 may disrupt the interaction between TR3 and
Nix by phosphorylation. In HeLa cells, co-application of THPN
and LY294002 significantly facilitated the interaction between
TR3 and Nix with the associated TR3 targeting to mitochondria,
which was reduced by the transfection of Myr-Akt2 but not a
dominant negative Akt2 (DN-Akt2), which lost the kinase activity
to phosphorylate TR3 (Figure 3B).
S341, S351, and S533 are three potential Akt2 phosphoryla-
tion sites in TR3 (Figure S3E). Analysis with mass spectrometry
indicated that S533 in LBD was phosphorylated by Akt2 (Fig-
ure S3F). Consistent with these data, single mutation of either
S341A or S351A in the full-length TR3 (TR3S341A or TR3S351A)
did not affect the phosphorylation of TR3 by Myr-Akt2, but
S533A (TR3S533A) did (Figure S3G). That S533 was the site for
Akt2 phosphorylation was also corroborated in an in vitro phos-
phorylation assay where Akt2 phosphorylated LBD but not
LBDS533A (Figure 3C).
Surprisingly, TR3S533A was able to translocate to cytoplasm
without any stimulation, while the other two mutants could not
(Figure S3H). Consequently, THPN directly triggered TR3S533A
interaction with Nix (Figure 3D), which facilitated TR3S533A trans-
location to mitochondria in the absence of LY294002 (Figure 3E).
As expected, either native TR3, TR3S341A, or TR3S351A required
both LY294002 and THPN for the interactions with Nix (Fig-
ure S3I). However, an S533D mutant (TR3S533D) that mimics
the phosphorylation of TR3 did not respond to THPN stimulation
to enhance the TR3 interactionwith Nix (Figure S3J), and failed to
target to mitochondria even in the presence of LY294002 (Fig-
ure 3E). This mutant restored neither the THPN-dependent
conversion of LC3 nor cell death, unlike either native TR3 in the
presence of LY294002 or S533A without LY294002 stimulation,
after transfection into the TR3-knockdownHeLa cells (Figure 3F).
All of these data support the notion that Akt2 phosphorylation of
TR3 at Ser533 impedes TR3 nucleocytoplasmic translocation
and THPN-induced interaction with Nix, as well as the subse-
quent autophagic cell death.
Differential Binding of Compounds to LBD Determines
Their Interaction with Nix
The structure of THPN features a core benzene ring functional-
ized by an acyl group at position 1 and three hydroxyl groups
at positions 3, 4, and 5. To make the compound more generally
applicable, a series of compounds derived from THPN was
generated by varying the length of the acyl group and the posi-
tion of three hydroxyl groups (Figure 4A). All of these compounds
bound LBD, as was demonstrated by a quenching assay (Fig-
ure S4A). The complexes between the compounds and LBD
were also generated and crystallized for structural analysis,
which showed that acyl moieties of these compounds bound
LBD in a similar fashion (Figure S4B). In addition, their potency
in inhibiting HeLa cell viability in the presence of LY294002
was evaluated by flow cytometry. Among these compounds,
compound 4, with 10 carbon atoms in the acyl group, had(F) TR3S553A, but not TR3S533D, rescues the THPN-induced LC3 conversion and
Cells were then stably transfected with various siRNA-resistant TR3 mutations. T
was determined by flow cytometry after THPN treatment (20 mM, for 24 and 48 hr
experiments. ***p < 0.001.
See also Figure S3.
Chemistry & Biology 22, 1040–the best potency in impairing HeLa cell viability and inducing
LC3 conversion (Figure 4B). A similar phenomenon was also
observed with melanoma cells A375 without LY294002 (Fig-
ure S4C). A combined treatment of compound 4 and
LY294002 led to a significantly enhanced interaction between
TR3 and Nix, TR3 trafficking to mitochondria, and DJm dissipa-
tion over THPN treatment in HeLa cells (Figure 4C) and mela-
noma A375 cells without LY294002 (Figure S4D). These results
indicate that compound 4 is highly effective in cancer cell death
through the TR3-mediated autophagic pathway.
It is clear that the optimal length of the acyl chain is of great
importance to the potency. The acyl groups of compounds 3,
4, and 5 occupied the same cavity in LBD as that in THPN,
with the similar location and orientation for the 3,4,5-trihydroxy-
benzene moiety (Figure 4D). Comparing the complex structures
among compounds 3, 4, 5, and THPN, the acyl group from com-
pound 4 has a snug fit in the binding pocket, while compound 3
and THPN, which were either two or one carbon atoms shorter,
did not fill up the pocket (Figure 4D). The acyl chain for com-
pound 5 was too long and the two atoms at the end of the chain
were missing electron densities, indicating a poor fit (Figure 4D;
Figure S4B). These data are in good agreement with those of ac-
tivity assays (Figure 4B), suggesting that an optimal occupation
of acyl chain in the cavity is required for the trihydroxybenzene
groups to adopt the pose for the highest biological potency.
The shorter chain in compound 2 left a considerable space in
the cavity. To further corroborate the notion that the full occupa-
tion of the space is beneficial for the activity, a mutation at L449
was made to fill the void with the bulkier Trp side chain (L449W).
Complex structural analysis showed that acyl moiety of com-
pound 2 had a snug fit in the now shallower cavity in LBDL449W
(Figure S4E). Consistent with the structural data, compound 2
greatly enhanced the interaction between LBDL449W and Nix,
and facilitated TR3L449W translocation to mitochondria (Fig-
ure 4E), LC3 conversion, and HeLa cell death in rescue experi-
ments with endogenous TR3 knocked down in the presence of
LY294002 (Figure S4F). Clearly, a suitable length of the acyl
group is of great importance for the compound to fill in the space
and shore up the 3,4,5-trihydroxybenzene moiety for a proper
surface for the interaction with Nix.
The 3,4,5-trihydroxybenzene moieties for compound 4 and
THPN in the complex structures of LBD and compound 2 in
the complex structure with LBDL449W are closely placed, which
forms part of the essential surface for the interaction with Nix
(Figure 4D; Figure S4E). The requirement for optimal placement
and orientation of the trihydroxybenzene moiety can also be
demonstrated. In compound 6, the trihydroxyl groups at posi-
tions 3, 4, and 5 are moved to positions 2, 3, and 4. In the com-
plex structure between compound 6 and LBD, the acyl moiety
occupied the same cavity but the trihydroxybenzene moiety
adopted a completely different pose of about 90 from that for
other compounds (Figure S4G). Consistently, compound 6 lost
the capability to induceLC3conversion and cell death (Figure 4B;cell death. Endogenous TR3 in HeLa cells was first knocked down by shRNA.
he LC3 conversion (top) was detected by western blot, and cell death (bottom)
, respectively). All data are presented as the mean ± SEM of three independent
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Figure 4. Compound 4 Induces Autophagic
Cell Death with High Efficacy
(A) Compounds (Comp.) used in this study.
(B) Compound-induced LC3 conversion and cell
death. HeLa cells were separately treated with or
without LY294002 (20 mM, 1 hr) before various
compounds. Top: Cell survival was determined by
flow cytometry after treatment with the com-
pounds (20 mM, 48 hr). Bottom: The LC3 conver-
sion was analyzed by western blot after treatment
with the compounds (20 mM, 24 hr). All data are
presented as the mean ± SEM of three indepen-
dent experiments. *p < 0.05; **p < 0.01; ***p <
0.001; NS, not significant.
(C) Effect of compound 4 on TR3-Nix interaction,
TR3 mitochondria targeting, and DJmdissipation.
HeLa cells transfected with various plasmids were
first treated with LY294002 (20 mM, 1 hr), and then
with either compound 4 (20 mM) or THPN (20 mM)
for 3, 6, or 12 hr for the analysis of TR3-Nix inter-
action (top), TR3 targeting to mitochondria (mid-
dle), and DJm dissipation (bottom).
(D) Compound binding in the complex structures.
Top: Stick drawings of superposition of THPN (in
magenta) with compound 3 (left, in black), com-
pound 4 (middle, in light orange), and compound 5
(right, in lemon). Bottom: The compound binding in
space-filling model. Compound 4 has the best fit in
LBD (ribbon diagram in cyan), while both com-
pound 3 and THPN are too short and compound 5
is missing density for the terminal atoms.
(E) Compound-associated LBDL449W interaction
with Nix and targeting to mitochondria with or
without LY294002. Top: GST-Nix interaction with
His-LBDL449W in the presence of various com-
pounds (20 mM), as analyzed by western blotting.
Bottom: HeLa cells were transfectedwith plasmids
as indicated. HeLa cells were pretreated with
LY294002 (20 mM, 1 hr) and then by different
compounds (20 mM, 6 hr), and analyzed for tar-
geting to mitochondria.
See also Figure S4.Figure S4C). Therefore, the correct orientation and location of
the trihydroxybenzene moiety are indeed essential for the
optimal interaction between TR3 and Nix.
Physiological Role of Compounds in Inhibition
of Neoplasm Growth
The synergy between THPN and Akt inhibitor for therapy was
tested by cell clone formation. THPN alone could not inhibit
HeLa cell clone formation, but its co-application with
LY294002 was able to do so in a dose-dependent manner
with THPN (Figure 5A, left). Similarly, THPN alone was suffi-
cient to inhibit the clonogenic survival in HeLa cells with Akt2
knockdown, but not with Akt1 knockdown (Figure 5B). Com-
pound 4 also showed no influence on the clonogenesis of
HeLa cells, unless it was co-applied with LY294002 (Figure 5A,1046 Chemistry & Biology 22, 1040–1051, August 20, 2015 ª2015 Elsevier Ltd All rights reseright). As expected, melanoma A375
cells responded better to compound 4
than to THPN in clone formation assays,
unless TR3 was knocked down, inwhich case both compound 4 and THPN lost their potency
(Figure S5A).
A xenografted model in immunodeficient mice was also
used to evaluate the synergy between THPN and Akt inhibitor.
Two weeks after injection of HeLa cells, palpable tumors were
present in all animals, which were treated with DMSO
(vehicle), THPN, LY294002, Akt inhibitor XII, or their combina-
tion as indicated. In the vehicle group, the physiological asso-
ciation of TR3 with Akt2 could be clearly detected (Fig-
ure S5B), while mice treated with a combination of either
THPN and LY294002 or THPN and Akt Inhibitor XII showed
significant tumor repression compared with the controls or
mice treated with single compounds (Figure 5C). In melanoma
A375 cells, where Akt activity is relatively low, the THPN treat-
ment alone was sufficient to inhibit the tumorigenesis.rved
Figure 5. Anti-tumor Activity of Compound 4 and THPN Requires LY294002 for Non-melanoma Cancer Cells
(A) Dose-dependent inhibition of colony formation for THPN and compound 4 in the presence of LY294002 (5 mM). Compound 4 has higher potency in HeLa cells.
(B) THPN could inhibit the colony formationwithout LY294002 if endogenous Akt2 was knocked down in HeLa cells. Knockdown of Akt1 was used as the negative
control.
(C) Inhibition of tumor growth by THPN with the presence of LY294002 or Akt Inhibitor XII in the xenograft model. HeLa cells (107 cells/per mouse) were injected
subcutaneously into the flanks of nude mice (n = 7) to generate xenograft tumors. Mice were treated with either THPN (10 mg/g), LY294002 (10 mg/g), Akt Inhibitor
XII (5 mg/g), or their combination as indicated, every other day for 2 weeks. The control group received 4% Tween 80/PBS only. Representative images of
xenografts (left; scale bars, 10 mm) and tumor weights (right) are shown.
(D) Compound 4 displays better inhibition of the tumor formation in the lung and liver than does THPN. Melanoma B16 cells (53 105 cells/mouse) were injected
subcutaneously into C57BL/6J (n = 8). Mice were administered with THPN (10 mg/g) or compound 4 (10 mg/g) every other day for 2 weeks. The images of tumors
formed in the lung and liver are indicated (top; scale bars, 5 mm), and tumors counted (bottom).
(E and F) Effects of THPN or compound 4 on LC3 conversion. Tumor samples were collected randomly from each group indicated in (C) and (D), and LC3
conversion was analyzed by western blot.
All data are presented as the mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant. See also Figure S5.However, when TR3 was knocked down, the inhibition of
THPN on tumor transplantation was no longer observed (Fig-
ure S5C). Furthermore, compound 4 functioned more signifi-
cantly on A375 cell xenograft regression than did THPN in
immunodeficient mice (Figure S5D). It is evident from these
data that THPN plays a specific role in inhibiting melanoma
with TR3 mediation, while Akt interferes with the role of
THPN in other cancer types.Chemistry & Biology 22, 1040–Compound 4 is also more effective in reducing the melanoma
B16 clones in lung and liver of C57BL/6Jmice, another model for
tumor, compared with THPN at the same concentration by intra-
venous injection (Figure 5D). Judging by the conversion of LC3 in
tumor samples (Figures 5E and 5F; Figures S5E and S5F), it is
evident that these compounds can suppress the growth of
various tumor types through the autophagic pathway with
dependence on the Akt activity. Combined treatment of THPN1051, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1047
and LY294002 on xenograft led to a significantly enhanced inter-
action between TR3 and Nix, which was not observed in the
groups treated with THPN or LY294002 alone (Figure S5G).
Therefore, attenuating Akt activity is critical for THPN-induced
autophagic cell death in cancer types other than melanoma.
DISCUSSION
Although proapoptotic drugs have been the main chemothera-
peutic agents in medical oncology to date, increasing evidence
indicates that many types of cancer can develop apoptotic resis-
tance. For example, cisplatin has been used as an apoptosis
inducer in clinical administration for cancer types such as breast,
bladder, ovarian, gastric, and cervical. However, abnormalities in
caspase deficiencies and Bcl-2 overexpression lead to tumor-
resistant to cisplatin treatment (Blanc et al., 2000; Cho et al.,
2011; Dasari and Bernard Tchounwou, 2014; Ho et al., 2014;
Kong et al., 2011; Liu et al., 2012). It is important to develop novel
therapeutic strategies to solve the emerging problem of
apoptotic resistance. Autophagy has been characterized as a
critical homeostatic and adaptive process to modulate cell
fate. Proper controlled autophagy benefits cell survival due to
its role in macromolecular synthesis and ATP production, while
excessive degradation of intracellular constituents is a self-
limiting property of autophagy that ultimately leads to cell death
(Marino et al., 2014; Wirawan et al., 2012; Yorimitsu and Klion-
sky, 2005). Recently, we reported that THPN effectively induces
autophagic cell death inmelanoma that is notoriously resistant to
apoptosis (Wang et al., 2014). Here, we further devise a novel
strategy to combat other cancers, such as cervical and gastric
cancers, with THPN and similar compounds through a TR3-
mediated autophagic cell death instead of apoptosis. Melanoma
cells with lower Akt activity effectively respond to THPN-induced
autophagic cell death in a TR3-participating mitochondrial
signaling pathway. In contrast, higher Akt activity in non-mela-
noma cells leads to resistance to THPN treatment due to Akt2
phosphorylation of TR3 to retain TR3 in the nucleus. Thus, atten-
uation of Akt2 activity will allow THPN to trigger autophagic cell
death in non-melanoma cells.
The PI3K/Akt pathway, frequently hyperactive in cancer, is
considered to be one of the most important contributors to
the development of cancer cells with increased resistance to
chemotherapy and/or radiotherapy (Burris, 2013), where Akt
provides a clear target for PI3K signaling. For example, Akt in-
duces malignant cells resistant to cisplatin treatment through
a so-called off-target resistance mechanism (Galluzzi et al.,
2012; Mitsuuchi et al., 2000). Hence, Akt inhibitors have been
developed for the synergistic treatment of different types of tu-
mors. Perifosine, a widely used Akt inhibitor that sensitizes can-
cer cells to radiation for apoptotic induction, shows synergy
with traditional chemotherapeutic agents such as etoposide in
leukemia cells, doxorubicin in multiple myeloma cells, and te-
mozolomide in glioma cells (Hideshima et al., 2006; Momota
et al., 2005; Nyakern et al., 2006). Therefore, application of
Akt inhibitors in conjunction with various types of chemotherapy
has been conducted extensively in preclinical studies. This
study demonstrated that THPN alone is effective in treating mel-
anoma with low Akt activity, but less so in other cancer cells
with higher Akt activity. Co-application of either LY294002 or1048 Chemistry & Biology 22, 1040–1051, August 20, 2015 ª2015 ElAkt2 inhibitor XII, inhibitors to the PI3K/Akt pathway, greatly en-
hances the sensitivity of non-melanoma cancer cells to THPN.
This enforces the view that Akt is a key barrier in cancer therapy,
and broadens the application of THPN to non-melanoma cancer
types.
Akt itself has been shown to be an effective target for control-
ling cancer through autophagic signaling. In breast cancer cells,
ablation of Akt2 led to mitochondrial autophagy and eventually
cell death with the inhibition of the p70S6K signaling pathway
(Santi and Lee, 2011). 6-Shogaol induced autophagic, but not
apoptotic, cell death by blocking the activation of Akt and its
downstream target mTOR (mammalian target of rapamycin)
(Hung et al., 2009). This evidence lent support to the notion
that the inhibition of Akt activity is also beneficial to autophagy.
We discovered that Akt2 specifically participates in autophagic
regulation through phosphorylating its substrate TR3. Akt2
phosphorylation retained TR3 in the nucleus to prevent the
THPN-induced TR3 interaction with Nix, which disrupts a series
of signaling events that include TR3 mitochondrial translocation,
dissipation of DJm, and autophagic cell death. Therefore, abol-
ishing this specific interfering function of Akt2 to phosphorylate
TR3 provides a unique avenue for cancer therapy through the in-
duction of autophagic cell death.
Although Akt1, Akt2, and Akt3 share similar structures, each
enzyme has high substrate selectivity in vivo. It is evident that
the LBD of TR3 is responsible for Akt2 binding, while the N-ter-
minal transactivation domain of TR3 is the region for interaction
with Akt1 (Chen et al., 2008). This difference in interaction may
correlate with distinct functions. Akt2 phosphorylation of TR3
at Ser533 is responsible for anti-autophagy, while Akt1 phos-
phorylation of Ser351 in TR3 is associated with anti-apoptosis
(Han et al., 2006; Masuyama et al., 2001). Since Akt2 interferes
with the THPN-induced autophagy through a novel S533 site,
this Akt2 phosphorylation of TR3 may be the initial barrier to
impair THPN-associated mitochondrial depolarization and auto-
phagic cell death in THPN-resistant cancer cells.
This study demonstrates two key structural features for THPN
and its derivatives that are responsible for their interaction with
Nix. The acyl group contributes to the binding with LBD, which
requires a proper chain length to properly place and fix the trihy-
droxybenzene group for the formation of a functional surface.
The crystallographic characterization shows that compounds
2, 3, 4, and THPN bind at the same pocket with a similar pose.
Among these, compound 4 has the best fits in the pocket with
a corresponding high potency for inducing autophagy and cell
death, which is an indication that the decane group of compound
4 has the optimal fix of the trihydroxybenzene group for the TR3-
Nix interaction. Another important structural element is the orien-
tation of the trihydroxybenzene group. In compound 6, different
positions of three hydroxyl groups placed the functional trihy-
droxybenzene group in a different orientation from THPN to the
detriment of the TR3-Nix interaction, as shown by the crystallo-
graphic characterization. Therefore, the length of the acyl group
as well as the position and orientation of the three hydroxyl
groups are determinants of the interaction between TR3 and
Nix, which steers the cellular fate to autophagic death for mela-
noma and non-melanoma cancer.
In sum, this study not only provides an alternative route to
induce cellular demise via an autophagy pathway, but alsosevier Ltd All rights reserved
suggests that THPN and similar compounds can be a useful
complement to cancer treatment via a non-apoptotic pathway.
SIGNIFICANCE
Apoptotic resistance frequently develops during radio-
therapy and chemotherapy, which has become an obstacle
to the successful treatment of cancers. It is of great impor-
tance to develop novel therapeutic strategies to induce
cell death in cancers resistant to apoptosis. Previously we
identified a compound, THPN, that specifically induced au-
tophagic death in melanoma cells through its interaction
with orphan nuclear receptor TR3, but not in non-melanoma
cancer cells. In this study, we demonstrated that Akt2 is the
factor that nullifies the role of THPN in inducing TR3-medi-
ated autophagic signaling pathways in non-melanoma cells,
such as SGC7901 gastric cancer cells and HeLa cervical
cancer cells. The high activity of Akt2 in non-melanoma cells
phosphorylated TR3 to prevent its export from the nucleus
and subsequently shuttle to the mitochondria, a crucial
event in the TR3-mediated autophagy. Thus, a novel thera-
peutic strategy is developed with the co-application of an
Akt2 inhibitor and THPN for the treatment of non-melanoma
cancers to expand the application scope of THPN for over-
coming apoptotic resistance. A more powerful THPN deriv-
ative was generated to effectively suppress the tumorigen-
esis via a structure-based approach. Overall, this study
provides a molecular insight into the Akt2-associated resis-
tance to autophagy through interfering with a mitochondrial
signaling pathway, and demonstrates a new avenue for the
treatment of apoptotic-resistant cancers through the induc-
tion of autophagic cell death by broadening the application
of THPN with synergetic Akt inhibitors.
EXPERIMENTAL PROCEDURES
Mouse Models
Animals were maintained at the Experimental Animal Center in Xiamen Univer-
sity (China) according to the institutional guidelines. All animal experiments
were approved by the Animal Ethics Committee of Xiamen University
(XMULAC20120030). Compound was dissolved in 50% Tween 80, and further
diluted with PBS at different concentrations. The negative control was injected
with 4% Tween 80/PBS.
Xenograft Formation
Cancer cells that were transfected with either control shRNA or TR3 shRNA
were subcutaneously injected into the right flanks (107 cells/mouse for HeLa
cells and 5 3 106 cells/mouse for A375 cells) of athymic nude mice (BALB/c,
18–20 g, 6–7 weeks old). Compound (10 mg/g body weight) was then injected
into the tumor areas every other day. The nude mice were euthanized 2 weeks
after the treatment. The tumors were counted and removed for further
experiments.
Formation of Melanoma in Lung and Liver
B16 cells were injected into the lateral tail vein of 6-week-old C57BL/6J mice
(5 3 105 cells/mouse). Three days after inoculation, mice were divided into
vehicle and experimental groups. The compounds (20 mg/g body weight)
were injected through the tail vein three times a week. The mice were eutha-
nized after 14 days of treatment. Melanomas in the lungs and livers were
counted and isolated for further analysis.
In Vitro Kinase Activity Assay
His-TR3 or His-LBD were purified with Ni-NTA agarose, and washed with
Akt kinase assay buffer (Cell Signaling; Cat. No. 9802). The slurry was incu-Chemistry & Biology 22, 1040–bated with 1 mg of pure active Akt2 protein (BioVision; Cat. No.93-7702-5),
0.2 mM ATP, and kinase assay buffer in a total volume of 50 ml for 30 min.
The reaction was terminated by boiling in loading buffer and analyzed by
SDS-PAGE.Preparation of the Mitochondrial Fractions
The mitochondrial fraction was prepared using the Mitochondria Isolation Kit
(Thermo Scientific). In brief, cells were lysed by reagents A, B, and C and
centrifuged at 700 3 g (4C, 10 min) to obtain a post-nuclear supernatant.
The mitochondria were pelleted by centrifugation at 10,000 3 g (4C,
15 min), boiled in loading buffer, and analyzed by SDS-PAGE.Rate of Cell Survival
Cells were harvested and then resuspended in 1 ml of PBS containing 5 mg of
propidium iodide (PI). PI incorporation was quantified on an EPICS XL flow cy-
tometer (Beckman Coulter). PI-negative cells in normal size were considered
as viable cells.
For colony formation, cells were seeded in 60-mm dishes (2 3 104 cells per
well) and cultured for 12 days. Colonies were fixed with methanol and stained
with 0.1% crystal violet in 20% methanol for 15 min.Mitochondrial Membrane Potential
To obtain the DJm, cells were stained with JC-1 (10 mg/ml, 37C, 15 min) or
DiOC6 (40 nM, 37C, 20 min) under growth conditions, and then washed
with PBS and analyzed by an EPICS XL flow cytometer.Measuring the Permeability of Lysosomal Membrane
LysoTracker red DND-99 and AO were used as the lysosomotropic probes.
Cells were incubated with LysoTracker (75 nM) or AO (5 mg/ml) for 20 min at
37C, washed with DMEM, and observed under the confocal microscope.Statistical Analysis
Viability data are expressed as the mean ± SEM, and the statistical analysis of
the differences was determined with the two-tailed Student t test or ANOVA.
Statistical analysis was performed using SPSS Statistics 17.0.SUPPLEMENTAL INFORMATION
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